Source: Annual Congress 2012 - Viral infections and rare respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
H. Ishii, K. Komiya, H. Kushima, H. Oka, H. Mukae, J.I. Kadota (Yufu, Kitakyushu, Japan). Limited effect of clarithromycin in non-elderly, non-severe patients with influenza. Eur Respir J 2012; 40: Suppl. 56, 2535

Member's Comments

No comment yet.

Related content which might interest you: Combination of nitazoxanide with oseltamivir compared with oseltamivir in hospitalized patients with influenza Source: Virtual Congress 2020 – Respiratory viruses in the "pre COVID-19" era Year: 2020 Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues Year: 2015 Duration of therapy in hospitalised patients with CAP Source: Annual Congress 2007 - An international perspective of the management of hospitalised patients with community-acquired pneumonia Year: 2007 Six months azithromycin treatment in COPD patients with high risk of further exacerbations Source: International Congress 2017 – Management of COPD Year: 2017 Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003 Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004) Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Efficacy of influenza and pneumococcal vaccinations among patients with COPD Source: Annual Congress 2007 - Treatment of COPD Year: 2007 Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006 Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003 Comparison of efficacy of grippe vaccination in asthma and COPD patients Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Timing of previous hospitalizations impacts outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Differences between asthmatics and nonasthmatics hospitalised with influenza A infection Source: Eur Respir J 2013; 41: 824-831 Year: 2013 Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006